The lung microbiome in end-stage Lymphangioleiomyomatosis

Abstract

Abstract Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease with mortality driven primarily by respiratory failure. Patients with LAM frequently have respiratory infections, suggestive of a dysregulated microbiome. Here we demonstrate that end-stage LAM patients have a distinct microbiome signature compared to patients with end-stage chronic obstructive pulmonary disease.

Keywords

• Lymphangioleiomyomatosis
• Microbiome